EU project on intelligent materials to regenerate bone tissue

More than half a million Europeans suffer from disorders in or serious defects of some part of their bone structure. So, graft or implant operations needed to repair the damage depend decisively on the materials used. The Nanobiocom project, funded under the EU's Sixth Framework Programme (FP6), is working on the regeneration and repair of bone tissue. Its aim is to come up with a substitute for bone tissue that can repair the bone and regenerate it in such a way that it will be able to carry out similar functions to those in its natural state.

In the case of significant deterioration of the bone, it may be necessary for the implant to provide both functional and physiological properties of the damaged item. In such circumstances, the bone implants have to comply with certain requisites capable of contributing to a reconstruction of the deteriorated bone tissue in the most efficient and least harmful way possible, without any serious repercussions. Another requirement involves the carrying out of the mechanical functions of the damaged bone while the desired regeneration takes place.

In addition, the solutions have to be capable of remedying particularly serious damage, such as those due to congenital deficiencies, degenerative illnesses, cancerous disorders and other damage caused by accidents. The implants required for this type of solutions are more complex and sophisticated than the small implants known until now.

So the Nanobiocom project will seek to develop a support (scaffold) made out of a compound material that is 'intelligent', proactive, and capable of repairing and regenerating bone tissue. For this purpose, it has to be bioactive, capable of acting on the tissue-generating system and its corresponding genes, as well as responding correctly to the physiological and biological changes, both internal and external, of that system.

It is also necessary for its size and shape characteristics, as well as its mechanical functions, to correspond with those of healthy bones.

The specific tasks of the three-year project are now on fine tuning the intelligent material, based on nanoparticles and of a biodegradable nature. Also in the pipeline is the development of the cell culture in three dimensions, as well as ensuring the biocompatibility of the material.

Ultimately, the scientists involved in the frontier research project hope it will open new doors in the development of nanobiotechnology.

For more information, please visit:
http://nanobiocom.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...